RxDoctor Payments Data

Vasilis Makris, MD

Ophthalmology · Muncie, INNPI 1407827678

Payments from drug & device makers

$2,755in general payments, 2019–2025

Across 77 payments — averaging $35.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$993
  • Microsurgical Technology, Inc.$590
  • AbbVie$203
  • Kala Pharmaceuticals, Inc.$174
  • Biotissue Holdings Inc.$131
  • Mallinckrodt Hospital Products Inc.$116
  • plus $549 from 12 others

What the payments were for

  • Food & beverage$2,02073%
  • Education$1004%
  • Gifts$63523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,755 in reported general payments places this provider in the 65th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$431,934
Medicare patients
1,035
Services billed
6,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost66$38,332
RestasisCyclosporine17$21,475
RocklatanNetarsudil Mesylat/Latanoprost20$15,635
Prednisolone Acetate568$15,392
Latanoprost998$13,539
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$7,591
CombiganBrimonidine Tartrate/Timolol15$6,815
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat305$6,165
SimbrinzaBrinzolamide/Brimonidine Tart14$4,911
Brimonidine Tartrate62$3,199
TafluprostTafluprost/Pf14$2,549
Difluprednate13$908
Travoprost13$884
Timolol Maleate97$869
Dorzolamide Hcl22$652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$203$66,62298 claims
Aerie Pharmaceuticals, Inc.Rocklatan$17$15,63520 claims
AlconSimbrinza$993$4,91114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →